Pharmacokinetics and safety of silibinin in horses

American Journal of Veterinary Research

Volumn 74, Issue 10, 2013, Pages 1327-1332

  Hackett, Eileen S ^a   Mama, Khursheed R ^a   Twedt, David C ^a   Gustafson, Daniel L ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARINGENIN; SILIBININ;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NASOGASTRIC TUBE; NONHUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HORSES; INTUBATION, GASTROINTESTINAL; MASS SPECTROMETRY; MILK THISTLE; PLANT EXTRACTS; SILYMARIN;

EID: 84884805025     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.74.10.1327     Document Type: Article

References (18)

1. Hackett ES, Twedt DC, Gustafson DL. Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease. J Vet Intern Med 2013;27:10-16.
2. Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther 2007;6:146-157.
3. Saller R, Brignoli R, Melzer J, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008;15:9-20.
4. Saller R, Melzer J, Reichling J, et al. An updated systematic review of the pharmacology of silymarin. Forsch Komplementmed 2007;14:70-80.
5. Wen Z, Dumas TE, Schrieber SJ, et al. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 2008;36:65-72.
6. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25:139-146.
7. Filburn CR, Kettenacker R, Griffin DW. Bioavailability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharmacol Ther 2007;30:132-138.
8. Webb CB, Gustafson DL, Twedt DC. Bioavailability following oral administration of a silibinin-phosphatidylcholine complex in cats. Intern J Appl Res Vet Med 2012;10:107-112.
9. Wu JW, Lin LC, Hung SC, et al. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal 2007;45:635-641.
10. Weingand K, Bloom J, Carakostas M, et al. Clinical pathology testing recommendations for nonclinical toxicity and safety studies. AACC-DACC/ASVCP Joint Task Force. Toxicol Pathol 1992;20:539-543.
11. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03, 2010. Available at: www.evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf. Accessed Aug 1, 2011.
12. US FDA. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. Available at: www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM174090.pdf.US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research; 2009. Accessed Aug 1, 2011.
13. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10:193-203.
14. Schrieber SJ, Hawke RL, Wen Z, et al. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos 2011;39:2182-2190.
15. Hawke RL, Schrieber SJ, Soule TA, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 2010;50:434-449.
16. Lorenz D, Lucker PW, Mennicke WH, et al. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol 1984;6:655-661.
17. Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 2008;36:1909-1916.
18. Barton MH. Disorders of the liver. In: Reed SM, Bayly WM, Sellon DC, eds. Equine internal medicine. 3rd ed. St Louis: Saunders Elsevier, 2010;939-975.